N4 Pharma’s Nuvec® Shows Oral Delivery Promise
Company Announcements

N4 Pharma’s Nuvec® Shows Oral Delivery Promise

N4 Pharma (GB:N4P) has released an update.

N4 Pharma PLC has announced promising results from its latest oral delivery research for Nuvec®, a cutting-edge system designed for cancer treatments and vaccines. The study, in collaboration with the University of Queensland, showed that Nuvec® successfully delivered a plasmid DNA payload in the intestine, which led to significant protein expression and a strong antibody response. CEO Nigel Theobald expressed confidence in Nuvec®’s potential for various medical applications and outlined plans for continued research and development.

For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskN4 Pharma Engages Investors with CEO Q&A Session
TipRanks UK Auto-Generated NewsdeskN4 Pharma Showcases Strategic Focus and Growth Plans
TipRanks UK Auto-Generated NewsdeskN4 Pharma Advances in Vaccine and Cancer Delivery
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App